Leiden, The Netherlands, August 17, 2010. Biotech company Pharming Group NV
("Pharming") (NYSE Euronext: PHARM) today announced that its current number of
outstanding shares has increased from 332,865,044 at August 5, 2010 to
341,243,169 as per today.
The increase of 8,378,125 shares stems from:
* 4,166,667 shares issued under the Standby Equity Distribution Agreement
("SEDA") with YA Global Master SPV LTD ("YA Global") for a cash
consideration of €750,000. As per today, approximately €22.7 million remains
available under the total €30.0 million SEDA facility with YA Global as
entered into in 2009;
* an aggregate number of 4,211,458 shares for the conversion of €0.5 million
bonds at an exercise price of €0,12. This conversion relates to the €7.5
million January 2010 private bonds. As a result, the original nominal value
of the bonds has decreased to €0.4 million today.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic
disorders, specialty products for surgical indications, and nutritional
products. On June 24, the European Medicines Agency adopted a positive opinion
for Ruconest(TM) (Rhucin) for the treatment of angioedema attacks. Market
Authorization in the European Economic Area is therefore expected to be granted
in September 2010. The product is also under development for follow-on
indications, i.e. antibody-mediated rejection (AMR) and delayed graft function
(DGF) following kidney transplantation. The advanced technologies of the Company
include innovative platforms for the production of protein therapeutics,
technology and processes for the purification and formulation of these products.
Recently, the partial spin-off of DNage was completed. Additional information is
available on the Pharming website,http://www.pharming.com.
This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.
Contact:
Ms. Marjolein van Helmond, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54
[HUG#1438504]
Press release (PDF):
http://hugin.info/132866/R/1438504/382995.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Pharming Group N.V. via Thomson Reuters ONE
